Skip to main content
. 2021 Dec 7;11:23529. doi: 10.1038/s41598-021-03074-5

Table 2.

Baseline demographic and clinical characteristics of SLE patients.

All (N = 259) Thrombotic events (n = 27) No event (n = 232) P-value
Age at onset of SLE, years 34.0 ± 13.7 35.1 ± 14.2 33.9 ± 13.6 0.646
Females (%) 239 (92.3) 24 (88.9) 215 (92.7) 0.486
Disease duration, months 2.87 ± 5.44 3.68 ± 4.79 2.77 ± 5.51 0.412
Ever smoker (former or current) (%) 15 (5.8) 3 (11.1) 12 (5.2) 0.196
Diabetes mellitus (%) 6 (2.3) 0 (2.7) 6 (2.6) 0.513
Hypertension (%) 98 (37.8) 17 (63.0) 81 (34.9) 0.004
SLEDAI-2K score 10.7 ± 6.18 12.1 ± 6.53 10.5 ± 6.13 0.219
Met the ACR-97 criteria (%)
Malar rash 131 (60.6) 10 (37.0) 121 (52.2) 0.137
Discoid rash 26 (10.0) 1 (3.7) 25 (10.8) 0.214
Photosensitivity 81 (31.3) 7 (25.9) 74 (31.9) 0.527
Oral ulcer 47 (18.1) 2 (7.4) 45 (19.4) 0.096
Arthritis 114 (44.0) 10 (37.0) 104 (44.8) 0.440
Pleuritis 31 (12.0) 2 (7.4) 29 (12.5) 0.344
Pericarditis 23 (8.9) 4 (14.8) 19 (8.2) 0.206
CNS involvement 21 (8.1) 5 (18.5) 16 (6.9) 0.036
Renal involvement
Proteinuria 96 (37.1) 15 (55.6) 81 (34.9) 0.036
Hematuria 70 (32.0) 13 (48.1) 70 (30.2) 0.058
Pyuria 67 (25.9) 9 (33.3) 58 (25.0) 0.349
Hematological involvement
Lymphopenia 201 (77.6) 20 (74.1) 181 (78.0) 0.642
Anemia 78 (30.1) 9 (33.3) 69 (29.7) 0.700
Thrombocytopenia 66 (25.5) 8 (29.6) 58 (25.0) 0.601
Concomitant disease (%)
Interstitial lung disease 10 (3.9) 2 (7.4) 8 (3.4) 0.280
Raynaud’s phenomenon 60 (23.2) 4 (14.8) 56 (24.1) 0.202
Anti-phospholipid syndrome 13 (5.0) 6 (22.2) 7 (3.0) 0.001
Associated Sjögren’s syndrome 27 (10.4) 4 (14.8) 23 (9.9) 0.305
Thyroid disease 20 (7.7) 1 (3.7) 19 (8.2) 0.357

Except where otherwise indicated, data are presented as the mean ± standard deviation.

Abbreviations: CNS, central nervous system; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index.